News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
New and experimental HIV treatments
1 Year After Approval: How Does D/C/F/TAF Measure Up?

The US Food and Drug Administration (FDA) approved the first darunavir-based single-tablet regimen (STR) for the treatment of HIV in July 2018. Now, nearly a year since its launch, health care practitioners and patients alike are evaluating its place in the HIV treatment landscape.

Published
01 July 2019
From
Contagion Live
Transgender people
Once Engaged in Care, Trans Women Have High Rates of HIV Suppression

Continuum of care review finds 80% of transgender women in care achieve an undetectable viral load.

Published
01 July 2019
From
POZ
Microbicides
Novel HIV-1 Inhibitor Shows Promise for Future Treatment of HIV in Women

Avirulins may provide a valuable chemical foundation for the development of the next generation of prophylactic medications for HIV-1 in women, according to results of a study presented at American Society of Microbiology (ASM) Microbe 2019 held from June 20-24, 2019, in San Francisco, California.

Published
26 June 2019
From
Infectious Disease Advisor
Side-effects
Cases of hair loss among African-American women reported after switch to new tenofovir formula

Hair loss (alopecia) occurred in six African-American women living with HIV after switching to the new formula of tenofovir, clinicians report in Open Forum Infectious Diseases. The

Published
26 June 2019
By
Michael Carter
Resistance
Genotype Testing at HIV Diagnosis Provides No Benefit

For the majority of people with HIV in the US, the current treatment guidelines recommend an integrase strand inhibitor paired with an NRTI as first-line ART. Therefore, baseline genotype results currently guide the choice of initial NRTI pair, given transmitted NRTI resistance (NRTI-R). With this evolution of HIV treatment, the role and value of baseline genotype testing has become uncertain. This study determined the clinical and economic value of baseline genotype testing for people newly diagnosed with HIV in the US.

Published
25 June 2019
From
Infectious Disease Advisor
Adherence
Researchers Discuss Ethics and Privacy Concerns About the Growing Field of HIV Adherence Monitoring

We have several ways to measure adherence to treatment or pre-exposure prophylaxis (PrEP). But as technology changes, and the fields of HIV medicine and public health focus increasingly on monitoring viral suppression or drug concentrations in the body for PrEP, the questions about the ethics of certain technologies, their uses, and what happens to that data are still being debated.

Published
25 June 2019
From
The Body Pro
The search for a cure
Disabling CCR5 Could Be Key to a Cure—but at What Cost?

Interfering with this receptor on immune cells could have harmful health consequences.

Published
25 June 2019
From
Poz
Long-acting HIV treatment
Study Finds Long-Acting HIV Meds Are Acceptable to Many People, but Differences Exist Among Groups

Now that long-acting antiretroviral therapy (LA-ART) is nearly a reality, is it something that people with HIV will prefer over once-daily pills? A study presented during a poster session at the International Conference on HIV Treatment and Prevention Adherence tried to find out whether LA-ART was as acceptable as daily-pill ART among 374 people living with HIV in a clinic in Houston. While they found that overall, LA-ART was acceptable among a majority of people, it wasn't equally acceptable among all groups.

Published
25 June 2019
From
The Body Pro
Side-effects
Major HIV drug calls for vigilance

A study lead by researchers at the Institute of HIV Research, Medical Faculty of UDE and University Hospital Essen, stumbled over a potential toxicity of integrase inhibitors. The researchers found that INSTI had a dramatic effect on activity of immune cells and in particular reduced the activity and function of CD4 T helper cells. This included a reduced proliferation and multiplication of these cells.

Published
24 June 2019
From
University of Duisberg-Essen
Child developmental issues
Antiretrovirals do not cause neurodevelopmental harm to uninfected infants

In the first five years of life the neurological development of HIV-exposed but uninfected infants, exposed to maternal antiretrovirals before and after birth and throughout breastfeeding, is comparable

Published
24 June 2019
By
Carole Leach-Lemens
← Prev12345...508Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.